Pharmacogenomics in cardiovascular diseases

Progress in Cardiovascular Diseases

Volumn 44, Issue 6, 2002, Pages 479-498

  Mukherjee, Debabrata ^a,b   Topol, Eric J ^a,b  

^a UNIVERSITY OF MICHIGAN   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; AZATHIOPRINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CAPTOPRIL; CISAPRIDE; CLARITHROMYCIN; CODEINE; DEBRISOQUINE; DIGOXIN; DISOPYRAMIDE; ENALAPRIL; FIBRINOLYTIC AGENT; FLECAINIDE; LISINOPRIL; MEFLOQUINE; MERCAPTOPURINE; MIBEFRADIL; PHENYLEPHRINE; PHENYTOIN; PROPAFENONE; QUINIDINE; RAMIPRIL; SALBUTAMOL; SIMVASTATIN; SPARTEINE; TERFENADINE; TIOGUANINE; UNINDEXED DRUG; WARFARIN;

CARDIOVASCULAR DISEASE; DRUG ABSORPTION; DRUG EFFICACY; DRUG EXCRETION; DRUG METABOLISM; DRUG SAFETY; DRUG TARGETING; GENETIC POLYMORPHISM; HUMAN; MORBIDITY; MORTALITY; PHARMACOGENOMICS; REVIEW;

EID: 0036085607     PISSN: 00330620     EISSN: None     Source Type: Journal    
DOI: 10.1053/pcad.2002.123467     Document Type: Article

References (139)

1. Pharmacogenomics: Translating functional genomics into rational therapeutics
2. Pharmacogenetics of cancer therapy: Getting personal
3. Impact of environmental and genetic factors on codeine analgesia
4. The sequence of the human genome
5. Initial sequencing and analysis of the human genome
6. Incidence of adverse drug reactions in hospitalized patients: A meta-analysis of prospective studies
7. Counting the costs of drug-related adverse events
8. Impact of genomics on drug discovery and clinical medicine
9. Pharmacogenomics: A clinician's primer on emerging technologies for improved patient care
10. Pharmacogenomics and the changing face of clinical pharmacology
11. The relationship between dose of succinylcholine and duration of apnea in man
12. On distribution and inheritance of atypcal forms of human serum cholinesterase as indicated by dibucaine numbers
13. Identification of the structural mutation responsible for the dibucaine- resistant (atypical) variant form of human serum cholinesterase
14. N-acetylation pharmacogenetics
15. Molecular mechanism of slow acetylation of drugs and carcinogens in humans
16. Disease and acetylation polymorphism
17. Characterization of the common genetic defect in humans deficient in debrisoquine metabolism
18. Clinical observations on the effects of debrisoquine sulphate in patients with high blood-pressure
19. The human CYP2D locus associated with a common genetic defect in drug oxidation: A G1934 - A base change in intron 3 of a mutant CYP2D6 allele results in an aberrant 3′ splice recognition site
20. Polymorphic hydroxylation of Debrisoquine in man
21. Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultra-rapid metabolism of debrisoquine
22. High blood concentrations of imipramine or clomipramine and therapeutic failure: A case report study using drug monitoring data
23. Molecular basis for rational megaprescribing in ultrarapid hydroxylators of debrisoquine
24. Thiopurine methyltransferase biochemical genetics: Human lymphocyte activity
25. Human liver thiopurine methyltransferase pharmacogenetics: Biochemical properties, liver-erythrocyte correlation and presence of isozymes
26. Science, medicine, and the future: Pharmacogenetics
27. Thiopurine methyltransferase pharmacogenetics: Alternative molecular diagnosis and preliminary data from Northern Portugal
28. Pharmacogenetics as a molecular basis for individualized drug therapy: The thiopurine S-methyltransferase paradigm
29. Clinical pharmacokinetics of mibefradil
30. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer
31. Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene
32. Phase II study of weekly intravenous trastuzumab (Herceptin) in patients with HER2/neu-overexpressing metastatic breast cancer
33. Overview of the trastuzumab (Herceptin) anti-HER2 monoclonal antibody clinical program in HER2-overexpressing metastatic breast cancer
34. Pharmacogenomics at work
35. The role of HER-2 expression in predicting response to therapy in breast cancer
36. Not quite pharmacogenomics
37. Big pharma hedges its bets
38. Pharmacogenomics: The promise of personalized medicine
39. Genes and the heart: A quest for new therapeutic strategies
40. Ultrafast analysis of DNA by microchip and nanochip technology
41. Pharmacogenomics and diagnostics
42. Identification of the breast cancer susceptibility gene BRCA2
43. Biochips: An evolving clinical technology
44. Cheap DNA arrays - It's not all smoke and mirrors
45. Molecular mechanisms of human hypertension
46. Mutations in the Na-Cl cotransporter reduce blood pressure in humans
47. Pharmacogenomics: A new approach to individual therapy of hypertension?
48. Adducin polymorphism affects renal proximal tubule reabsorption in hypertension
49. The role of alpha-adducin polymorphism in blood pressure and sodium handling regulation may not be excluded by a negative association study
50. Association of hypertension with T594M mutation in beta subunit of epithelial sodium channels in black people resident in London
51. Human hypertension caused by mutations in WNK kinases
52. Influence of genotype on the clinical course of the long-QT syndrome
53. Gene specific therapy for long QT syndrome: QT shortening lidocaine and tocainide in patients with mutation of the sodium channel gene
54. Long QT syndrome patients with mutations of the SCN5A and HERG genes have differential responses to Na+ channel blockade and to increases in heart rate. Implications for gene-specific therapy
55. Sodium channel block with mexiletine is effective in reducing dispersion of repolarization and preventing torsade des pointes in LQT2 and LQT3 models of the long-QT syndrome
56. Differential effects of beta-adrenergic agonists and antagonists in LQT1, LQT2 and LQT3 models of the long QT syndrome
57. Genotype-phenotype correlation in the long-QT syndrome: Gene-specific triggers for life-threatening arrhythmias
58. Genetically defined therapy of inherited long-QT syndrome. Correction of abnormal repolarization by potassium
59. A polymorphism of a platelet glycoprotein receptor as an inherited risk factor for coronary thrombosis
60. Platelet glycoprotein IIIa polymorphisms and risk of coronary stent thrombosis
61. Correlation of polymorphisms to coagulation and biochemical risk factors for cardiovascular diseases
62. A1/A2 polymorphism of glycoprotein IIIa and association with excess procedural risk for coronary catheter interventions: A case-controlled study
63. The Leu33/Pro polymorphism (PIA1/PIA2) of the glycoprotein IIIa (GPIIIa) receptor is not related to myocardial infarction in the ECTIM Study. Etude Cas-Temoins de l'Infarctus du Myocarde
64. PA1/A2 polymorphism of platelet glycoprotein IIIa and risks of myocardial infarction, stroke, and venous thrombosis
65. Platelet glycoprotein IIIa PI(a) polymorphism, fibrinogen, and platelet aggregability: The Framingham Heart Study
66. PIA polymorphism of platelet glycoprotein IIIa and risk of restenosis after coronary stent placement
67. Platelet glycoprotein IIIa polymorphism, aspirin, and thrombin generation
68. Increased binding of fibrinogen to glycoprotein IIIa-proline33 (HPA-1b, PIA2, Zwb) positive platelets in patients with cardiovascular disease
69. The future of antiplatelet therapy: Optimizing management in patients with acute coronary syndrome
70. Statin therapy is associated with reduced restenosis rates after coronary stent implantation in carriers of the PI(A2)allele of the platelet glycoprotein IIIa gene
71. The Platelet PIA2 and angiotensin-converting enzyme (ACE) D allele polymorphisms and the risk of recurrent events after acute myocardial infarction
72. The role of a common variant of the cholesteryl ester transfer protein gene in the progression of coronary atherosclerosis
73. Association of cholesteryl ester transfer protein-TaqIB polymorphism with variations in lipoprotein subclasses and coronary heart disease risk: The Framingham study
74. Association of TaqIB polymorphism in the cholesteryl ester transfer protein gene with plasma lipid levels in a healthy Spanish population
75. Apolipoprotein E as a risk factor for coronary heart disease: A genetic and molecular biology approach
76. The apolipoprotein epsilon4 allele determines prognosis and the effect on prognosis of simvastatin in survivors of myocardial infarction: A substudy of the Scandinavian simvastatin survival study
77. Apolipoprotein E4 allele as a predictor of cholinergic deficits and treatment outcome in Alzheimer disease
78. Cerebral metabolic and cognitive decline in persons at genetic risk for Alzheimer's disease
79. Statins and the risk of dementia
80. Atherosclerosis, apolipoprotein E, and prevalence of dementia and Alzheimer's disease in the Rotterdam Study
81. Brain infarction and the clinical expression of Alzheimer disease. The Nun Study
82. Role of the low-density lipoprotein receptor-related protein in beta- amyloid metabolism and Alzheimer disease
83. An apolipoprotein influencing triglycerides in humans and mice revealed by comparative sequencing
84. Haemostatic function and ischaemic heart disease: Principal results of the Northwick Park Heart Study
85. Polymorphisms in the factor VII gene and the risk of myocardial infarction in patients with coronary artery disease
86. Thrombosis prevention trial: Randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk. The Medical Research Council's General Practice Research Framework
87. Interpretation of Thrombosis Prevention Trial
88. A common thrombomodulin amino acid dimorphism is associated with myocardial infarction
89. Thrombomodulin Ala 455Val polymorphism and risk of coronary heart disease
90. Mutations in ABC1 in Tangier disease and familial high-density lipoprotein deficiency
91. Mutations in the ABC 1 gene in familial HDL deficiency with defective cholesterol efflux
92. Age and residual cholesterol efflux affect HDL cholesterol levels and coronary artery disease in ABCA 1 heterozygotes
93. Common genetic variation in ABCA1 is associated with altered lipoprotein levels and a modified risk for coronary artery disease
94. An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels
95. Clinical trials in pharmacogenetics and pharmacogenomics: Methods and applications
96. Relation between changes in blood pressure and serum ACE activity after a single dose of enalapril and ACE genotype in healthy subjects
97. ACE (I/D) genotype as a predictor of the magnitude and duration of the response to an ACE inhibitor drug (enalaprilat) in humans
98. Angiotensin I-converting enzyme gene polymorphism and acute response to captopril in essential hypertension
99. Deletion polymorphism in the gene for angiotensin-converting enzyme is a potent risk factor for myocardial infarction
100. D allele of the angiotensin-converting enzyme gene is a risk factor for secondary cardiac events after myocardial infarction
101. Pharmacogenetic interactions between beta-Blocker therapy and the angiotensin-converting enzyme deletion polymorphism in patients with congestive heart failure
102. Preprescription genotyping: Not yet ready for prime time, but getting there
103. The P-selectin gene is highly polymorphic: Reduced frequency of the Pro715 allele carriers in patients with myocardial infarction
104. Polymorphisms of the P-selectin gene and risk of myocardial infarction in men and women in the ECTIM extension study. Etude cas-temoin de l'infarctus myocarde
105. In search of perverse polymorphisms
106. Pharmacogenetic applications of the Human Genome project
107. How many medicines do patients with heart failure need?
108. Viewpoint - Pharmacogenetics and its impact on drug development
109. The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans
110. Troglitazone and liver function abnormalities: Lessons from a prescription event monitoring study and spontaneous reporting
111. Pharmacogenomics: Will the regulators approve?
112. New advances in pharmacogenomics
113. Hypertrophic obstructive cardiomyopathy due to a novel T-to-A transition at codon 624 in the beta-myosin heavy chain (beta-MHC) gene possibly related to the sudden death
114. Hypertrophic cardiomyopathy caused by a novel alpha-tropomyosin mutation (V95A) is associated with mild cardiac phenotype, abnormal calcium binding to troponin, abnormal myosin cycling, and poor prognosis
115. IRB review and consent in human tissue research
116. Pharmacogenetics and future drug development and delivery
117. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications
118. Genetic association between sensitivity to warfarin and expression of CYP2C9*3
119. Are poor metabolisers of sparteine/debrisoquine less pain tolerant than extensive metabolisers?
120. Clinical significance of the sparteine/debrisoquine oxidation polymorphism
121. The role of genetically determined polymorphic drug metabolism in the beta-blockade produced by propafenone
122. High incidence of secondary brain tumours after radiotherapy and antimetabolites
123. Role of the deletion of polymorphism of the angiotensin converting enzyme gene in the progression and therapeutic responsiveness of IgA nephropathy
124. Association between angiotensin-converting-enzyme gene polymorphism and failure of renoprotective therapy
125. Genetic and molecular basis of cardiac arrhythmias: Impact on clinical management part III
126. KVLQT1 C-terminal missense mutation causes a forme fruste long-OT syndrome
127. MiRP 1 forms IKr potassium channels with HERG and is associated with cardiac arrhythmia
128. Impact of genetic polymorphisms of the beta2-adrenergic receptor on albuterol bronchodilator pharmacodynamics
129. Functional polymorphisms of the human multidrug-resistance gene: Multiple sequence variations and correlation of one allele with P- glycoprotein expression and activity in vivo
130. G894T polymorphism in the endothelial nitric oxide synthase gene is associated with an enhanced vascular responsiveness to phenylephrine
131. Large-scale test of hypothesised associations between the angiotensin-converting-enzyme insertion/deletion polymorphism and myocardial infarction in about 5000 cases and 6000 controls
132. Thrombospondin genes associated with coronary artery disease. American Heart Association Annual Scientific Sessions
133. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients
134. Collaborative overview of randomised trials of anti-platelet therapy - I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients
135. Indications for fibrinolytic therapy in suspected acute myocardial infarction: Collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients
136. Reducing the risk of coronary events: Evidence from the Scandinavian Simvastatin Survival Study (4S)
137. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. The EPIC Investigation
138. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation